Bryophyllum E Fol. 5%

Dosage for Kalanchoe Daigremontiana Leaf extract is highly individualized and must be determined by a qualified allergist or immunologist. It is never self-administered by the patient for diagnostic purposes.

• Skin Prick Testing (SPT): Usually, a single drop of the extract (standardized to a specific PNU/mL concentration) is applied to the forearm or back. A sterile lancet is used to prick the skin through the drop. A positive control (histamine) and a negative control (saline) are used simultaneously for comparison.
• Intradermal Testing: If SPT is negative but clinical suspicion remains high, a 0.02 mL to 0.05 mL dose of a more dilute extract may be injected into the intradermal layer of the skin.
• Immunotherapy (Maintenance Dose): For those undergoing desensitization, the maintenance dose typically ranges from 0.5 mL of a 1:100 w/v to 1:1,000 w/v dilution, administered once every 2 to 4 weeks, depending on patient tolerance and clinical response.

Kalanchoe Daigremontiana Leaf extract may be used in children, but the procedure requires extreme caution.

• Children (Ages 5 and older): Dosing is generally similar to adults but may be initiated at a lower concentration to minimize the risk of a systemic reaction. The surface area for skin testing must be carefully managed.
• Children (Under Age 5): Not typically recommended unless the clinical need is significant and the risk-benefit ratio is carefully weighed by a pediatric allergist. The immune system of very young children is still developing, which may lead to inconsistent test results.

Renal Impairment

No specific dosage adjustments are generally required for renal impairment, as the systemic protein load is minimal. However, patients with end-stage renal disease should be monitored for delayed hypersensitivity reactions.

Hepatic Impairment

Hepatic impairment does not significantly alter the clearance of allergenic extracts. No formal dose adjustment guidelines exist for this population.

Elderly Patients

Elderly patients may have reduced skin reactivity (atrophy of the dermis), which can lead to false-negative skin test results. Healthcare providers may need to use higher concentrations for diagnostic accuracy in patients over 65.

This medication is administered exclusively by healthcare professionals in a clinical setting equipped to handle emergency allergic reactions.

• Preparation: The skin site is cleaned with alcohol and allowed to dry.
• Timing: Tests are usually read 15 to 20 minutes after application.
• Storage: The extract must be kept refrigerated at 2°C to 8°C (36°F to 46°F). Exposure to heat or freezing temperatures can denature the proteins and render the extract ineffective.
• Patient Instruction: Patients should avoid scratching the test site, as this can cause mechanical irritation and lead to a false-positive reading.

In the context of immunotherapy, a missed dose can disrupt the desensitization process. If a maintenance injection is missed:

• Less than 1 week late: The usual dose may often be given.
• 1 to 2 weeks late: The dose may need to be reduced by 25-50% to prevent a systemic reaction.
• More than 4 weeks late: The protocol may need to be restarted from a lower concentration.

An 'overdose' in this context refers to the administration of an excessively high concentration of allergen to a highly sensitized individual.

• Signs: Rapid onset of generalized hives, swelling of the throat (laryngeal edema), wheezing, drop in blood pressure, and loss of consciousness.
• Emergency Measures: Immediate administration of Epinephrine (0.3 mg intramuscularly for adults), oxygen, IV fluids, and antihistamines. All patients must be observed for at least 30 minutes following any injection of the extract.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients receiving Kalanchoe Daigremontiana Leaf extract will experience localized reactions at the site of administration. These are generally considered part of the diagnostic or therapeutic process rather than adverse events.

• Pruritus (Itching): Intense itching at the site of the skin prick or injection is very common. This typically begins within minutes and subsides within an hour.
• Erythema (Redness): A red 'flare' surrounding the test site is expected in sensitized individuals. This is caused by local vasodilation.
• Wheal Formation: A raised, pale bump (similar to a mosquito bite) is the hallmark of a positive skin test. It should be firm to the touch.
• Local Swelling: In immunotherapy, swelling at the injection site (up to the size of a half-dollar) is common and may last for 24 to 48 hours.

• Delayed Local Reactions: Some patients may develop swelling and redness at the site 6 to 24 hours after the test. This is often a late-phase allergic response.
• Fatigue: A general sense of tiredness or 'malaise' may occur following immunotherapy injections as the immune system processes the allergen.
• Headache: Mild to moderate headaches have been reported shortly after administration.

• Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the axilla or armpit if the injection was in the upper arm).
• Vasovagal Syncope: Fainting or lightheadedness, usually due to the stress of the needle stick rather than the extract itself.
• Generalized Urticaria: Hives appearing on parts of the body distant from the injection site.

> Warning: Stop taking Kalanchoe Daigremontiana Leaf and call your doctor immediately if you experience any of these.

• Anaphylaxis: This is a life-threatening systemic allergic reaction. Symptoms include a sudden feeling of warmth, a 'sense of impending doom,' swelling of the tongue or throat, and difficulty breathing.
• Bronchospasm: Sudden wheezing or chest tightness, particularly in patients with a history of asthma.
• Angioedema: Deep tissue swelling, most dangerously in the face, lips, or airway.
• Hypotension: A sharp drop in blood pressure, which may cause dizziness or fainting.

With prolonged use in immunotherapy, the most significant long-term 'side effect' is the intended change in the immune system. However, rare cases of 'serum sickness' (a Type III hypersensitivity reaction) have been historically noted with allergenic extracts, characterized by joint pain, fever, and rash, though this is extremely uncommon with modern, purified extracts. There is no evidence that Kalanchoe Daigremontiana Leaf extract causes cancer or organ damage with long-term use.

FDA Black Box Warning for Allergenic Extracts:

Allergenic extracts, including Kalanchoe Daigremontiana Leaf, can cause severe life-threatening systemic reactions, including anaphylaxis. These extracts should only be administered by healthcare professionals who are experienced in the diagnosis and treatment of allergic diseases and who are equipped to manage such reactions. Patients must be observed for at least 30 minutes after each injection. Patients with unstable asthma or those taking beta-blockers may be at increased risk for severe reactions or may be resistant to standard emergency treatments.

Report any unusual symptoms to your healthcare provider.

Kalanchoe Daigremontiana Leaf extract is a potent biological substance. It is vital that patients disclose their full medical history, including any previous reactions to plants, stings, or medications. Because this extract is designed to provoke an immune response, the line between a 'diagnostic result' and a 'serious reaction' can be thin. Safety is maintained through precise dosing and professional supervision.

No FDA black box warnings specifically for 'Kalanchoe' as a standalone entity, but it falls under the Universal Black Box Warning for Allergenic Extracts. This warning emphasizes the risk of anaphylaxis and requires administration in a facility equipped with 'crash carts' and emergency medications like epinephrine and oxygen. It also notes that the risk of a systemic reaction is higher during the 'build-up' phase of immunotherapy or when switching to a new lot of extract.

• Allergic Reactions / Anaphylaxis Risk: The primary risk is a systemic IgE-mediated reaction. Patients should be in their 'baseline' state of health before testing. If a patient is suffering from an acute infection or an asthma flare-up, the procedure should be postponed.
• Asthma Stability: Patients with poorly controlled or unstable asthma are at a significantly higher risk for severe bronchospasm following allergen exposure. A peak flow or spirometry test may be performed before administration.
• Cardiovascular Disease: Individuals with significant heart disease may be less able to tolerate the physiological stress of an allergic reaction or the effects of the epinephrine required to treat it.

• Observation Period: A mandatory 30-minute wait time in the clinic after administration is the standard of care.
• Skin Site Assessment: The healthcare provider will measure the diameter of the wheal and flare using a millimeter ruler.
• Pulmonary Function: In patients with respiratory symptoms, pre- and post-administration lung function monitoring may be required.

Most patients can drive after the 30-minute observation period. However, if a patient experiences a significant local reaction or mild systemic symptoms (like dizziness or fatigue), they should wait until these resolve before operating a vehicle.

Alcohol should be avoided for at least 24 hours after testing or immunotherapy. Alcohol can increase peripheral vasodilation, which may potentially accelerate the absorption of the allergen or worsen the severity of an allergic reaction.

Testing is a one-time event. For immunotherapy, discontinuation should be discussed with an allergist. There is no 'withdrawal' syndrome, but stopping immunotherapy prematurely will result in the return of original allergy symptoms.

> Important: Discuss all your medical conditions with your healthcare provider before starting Kalanchoe Daigremontiana Leaf.

• Beta-Blockers (e.g., Metoprolol, Propranolol): These medications are a major contraindication for allergen extracts. If a patient on a beta-blocker has an anaphylactic reaction to the Kalanchoe extract, the beta-blocker will prevent epinephrine from working effectively. This can lead to 'epinephrine-resistant anaphylaxis,' which is often fatal.

• ACE Inhibitors (e.g., Lisinopril): These may increase the risk of systemic reactions or worsen the severity of angioedema during allergen exposure.
• MAO Inhibitors (e.g., Phenelzine): These can interfere with the metabolism of epinephrine, potentially leading to a hypertensive crisis if emergency epinephrine is administered.

• Antihistamines (e.g., Loratadine, Cetirizine, Diphenhydramine): These medications must be stopped 3 to 7 days before skin testing. They block the H1 receptors, which prevents the 'wheal and flare' reaction, leading to a false-negative result. They do not, however, prevent the most dangerous systemic symptoms of anaphylaxis.
• Tricyclic Antidepressants (e.g., Amitriptyline): Like antihistamines, these have potent H1-blocking properties and can interfere with diagnostic accuracy.

• Cross-Reactive Foods: Some patients with Kalanchoe sensitivity may show cross-reactivity with other succulents or certain fruits. Discuss any 'oral allergy syndrome' symptoms (itching in the mouth after eating) with your doctor.
• Caffeine: High intake of caffeine may slightly increase heart rate, which could complicate the assessment of a systemic reaction.

• St. John's Wort: May theoretically affect the metabolism of medications used to treat allergic reactions.
• Licorice Root: May affect corticosteroid levels, which are sometimes used to treat late-phase allergic reactions.

• Skin Testing: Kalanchoe extract itself is the 'test.' However, recent use of topical steroids at the test site can suppress the skin's reactivity, leading to inaccurate results.
• Total IgE Levels: Immunotherapy may cause a transient rise in total IgE levels before they eventually decline.

For each major interaction, the mechanism involves either the suppression of the diagnostic response (pharmacodynamic) or the interference with emergency treatment (pharmacodynamic). Management involves stopping interfering medications (like antihistamines) well in advance of the procedure.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe, Unstable Asthma: Patients with an FEV1 (Forced Expiratory Volume) of less than 70% of their predicted value should not undergo testing or immunotherapy, as the risk of a fatal asthma attack is too high.
• Previous Anaphylaxis to Kalanchoe: If a patient has already had a life-threatening reaction to this specific extract, further exposure is strictly prohibited.
• Beta-Blocker Therapy: As detailed previously, the inability to respond to epinephrine makes the use of allergenic extracts unacceptably dangerous.

• Acute Infection: Testing should be delayed until the patient is afebrile (without fever) and symptoms have resolved.
• Severe Atopic Dermatitis: If the skin is extensively involved with eczema, there may be no 'clear' skin available for accurate testing.
• Pregnancy (Initiation): While maintenance immunotherapy is often continued during pregnancy, starting a new extract or increasing the dose is generally avoided due to the risk of maternal anaphylaxis and subsequent fetal hypoxia (lack of oxygen).

Patients who are allergic to Kalanchoe Daigremontiana may also react to:

• Kalanchoe blossfeldiana (Flaming Katy)
• Sedum species (Stonecrops)
• Other members of the Crassulaceae family.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Kalanchoe Daigremontiana Leaf.

FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Kalanchoe Daigremontiana Leaf extract should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The primary concern is not the extract itself, but the risk of systemic anaphylaxis in the mother, which can cause a sudden drop in placental blood flow and fetal distress. Most allergists will not start new testing or 'build-up' phases of immunotherapy during pregnancy.

It is not known whether the allergenic components of Kalanchoe Daigremontiana Leaf are excreted in human milk. However, because these are large proteins and the systemic dose is extremely low, it is generally considered safe to continue maintenance immunotherapy while breastfeeding. Diagnostic skin testing is also considered safe for nursing mothers.

Safety and effectiveness in children under the age of 5 have not been established. In older children, the extract is effective for diagnosis, but the emotional stress of the procedure and the risk of systemic reactions require a high level of clinical expertise. Pediatric patients should be monitored even more closely for 'delayed' reactions that may occur after they leave the clinic.

Clinical studies have not included sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased cardiac function and the potential for concomitant medications (like beta-blockers) that increase the risk of the procedure.

No specific studies have been conducted in patients with renal impairment. However, since the proteins are largely degraded by cellular proteases, significant accumulation of the active allergen is unlikely in patients with reduced kidney function.

No dosage adjustments are required. The liver does not play a primary role in the immediate immunological response to skin-applied allergens.

> Important: Special populations require individualized medical assessment.

Kalanchoe Daigremontiana Leaf extract contains specific antigens (likely glycoproteins) that act as 'allergens.' At the molecular level, these antigens bind to the Fab portion of IgE antibodies that are 'sensitized' on the surface of mast cells. This binding causes the IgE receptors (FcεRI) to cluster, which signals the mast cell to undergo exocytosis. During this process, pre-formed granules containing histamine and heparin are released into the extracellular space. This is followed by the de novo synthesis of lipid mediators like leukotriene C4. This cascade is the fundamental basis of the Type I hypersensitivity reaction.

• Dose-Response: There is a direct correlation between the concentration of the extract and the size of the wheal and flare, up to a 'saturation' point.
• Time to Onset: 5 to 10 minutes for initial redness; 15 to 20 minutes for peak wheal formation.
• Duration of Effect: The visible skin reaction usually fades within 2 to 4 hours, though a 'late-phase' reaction (swelling) can occur 6 to 12 hours later.

| Parameter | Value |

|---|---|

| Bioavailability | Negligible (Topical/ID); Low (SC) |

| Protein Binding | N/A (Interacts with IgE) |

| Half-life | Proteins: Minutes to Hours; Immunological Effect: Months |

| Tmax | 15 - 20 minutes (for skin reaction) |

| Metabolism | Cellular Proteolysis |

| Excretion | Renal (as peptide fragments) |

• Composition: A complex aqueous or glycerinated extract containing proteins, bufadienolides (in trace botanical amounts), and polysaccharides.
• Solubility: Highly soluble in aqueous buffers and 50% glycerin solutions.
• Molecular Weight: Ranges from 10 kDa to over 100 kDa for various allergenic protein fractions.

Kalanchoe Daigremontiana Leaf is classified as an Allergenic Extract. It is grouped with other botanical and environmental extracts used for 'In Vivo' diagnostic testing. It is distinct from 'In Vitro' tests like RAST or ImmunoCAP, which measure IgE in a blood sample.